The Globe and Mail reports in its Wednesday, May 17, edition that BMO Capital Markets analyst Joel Jackson is sticking with his "outperform" recommendation for Nutrien. The Globe's David Leeder writes in the Eye On Equities column that Mr. Jackson cut his share target to $90 from $110 (all figures U.S.). Analysts on average target the shares at $87.85. Mr. Jackson says in a note: "We now see 2023 EBITDA a little higher than the revised $7.2-billion guidance midpoint, and slightly lower 2024 EBITDA estimate to $6.5-billion, which we continue to deem a mid-cycle proxy. Our target is eight to 8.5 times 2024 estimated EV/EBITDA. We get it's tough to point out specific catalysts for [fertilizer] stocks like Nutrien currently, but believe that the stock represents good value currently assuming reratings come from investors ultimately feeling greater comfort levels around mid-cycle prices/earnings/multiples." The Globe reported on April 4 that RBC rated Nutrien "outperform." It was then worth $74.14. The Globe reported on April 11 that Scotia Capital analyst Ben Isaacson had upgraded Nutrien to "sector outperform" from "sector perform." The shares could then be had for $73.30.